JMT101

Phase 3Small molecule

CCSPC Megalith Biopharmaceutical Co.,Ltd.

JMT101 is one of 91 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerRecruiting

Metastatic Colorectal CancerNot yet recruiting

HNSCCNot yet recruiting

Non-Small Cell Lung CancerPhase 3

Recruiting

Metastatic Colorectal CancerPhase 3

Not yet recruiting

HNSCCPhase 2

Not yet recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Verzenio

Eli Lilly

Phase 3

6 2

Faslodex

FFresenius Kabi USA, LLC

Phase 3

4 3

HB1801

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

2 4

JMT101

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

6 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer

NCT06391944

Q2 2027

Phase 2Not yet recruiting

Nasopharyngeal Cancer

NCT06892431

Q4 2027

Phase 2/3Not yet recruiting

Non-Small Cell Lung Cancer

NCT06319313

Q1 2028

Phase 3Not yet recruiting

Non-Small Cell Lung Cancer

NCT06380348

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer6 trials

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Unknown status·SShanghai JMT-Bio Inc.·Phase 1·NCT04448379·48 enrolled

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Unknown status·SShanghai JMT-Bio Inc.·Phase 2·NCT05132777·155 enrolled

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2/3·NCT06319313·534 enrolled

Show 3 more trials

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT06735391·516 enrolled

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT06380348·398 enrolled

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Active, not recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT06391944·161 enrolled

Metastatic Colorectal Cancer2 trials

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT07134205·252 enrolled

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Unknown status·SShanghai JMT-Bio Inc.·Phase 2·NCT06089330·102 enrolled

Esophageal Squamous Cell Carcinoma1 trial

JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

Unknown status·PPeking University·Phase 1·NCT05164848·50 enrolled

Nasopharyngeal Cancer1 trial

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT06892431·150 enrolled

Advanced Solid Tumor1 trial

Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

Unknown status·SShanghai JMT-Bio Inc.·Phase 1·NCT04689100·259 enrolled

1 more indication

HNSCC1 trial

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 2·NCT06989671·430 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for JMT101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JMT101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JMT101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC Megalith Biopharmaceutical Co.,Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCSPC Megalith Biopharmaceutical Co.,Ltd.

JMT101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer6 trials

Metastatic Colorectal Cancer2 trials

Esophageal Squamous Cell Carcinoma1 trial

Nasopharyngeal Cancer1 trial

Advanced Solid Tumor1 trial

HNSCC1 trial

References

Drug Info

Quick Facts

Related News